| Dorshow, Richard B |
NCT05425719: Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects |
|
|
| Completed | 3 | 249 | US, RoW | MB-102, Relmapirazin, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) | MediBeacon | Chronic Kidney Disease | 02/23 | 02/23 | | |
NCT04008121: Feasibility and Safety of MB-102 in Ocular Angiography As Compared to Fluorescein Sodium |
|
|
| Not yet recruiting | 1 | 10 | US | Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system | MediBeacon | Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration | 06/25 | 06/25 | | |
| Paulus, Yannis |
NCT04008121: Feasibility and Safety of MB-102 in Ocular Angiography As Compared to Fluorescein Sodium |
|
|
| Not yet recruiting | 1 | 10 | US | Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system | MediBeacon | Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration | 06/25 | 06/25 | | |
| Hussain, Munira |
BRIDGET, NCT05323955: Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib |
|
|
| Recruiting | 2 | 48 | US | Trastuzumab, Herceptin, Trastuzumab Emtansine (T-DM1), Pertuzumab, Perjeta, Tucatinib, Tukysa | Carey Anders, M.D., Pfizer | Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer | 10/26 | 10/27 | | |
| Recruiting | N/A | 75 | US | Implantable Miniature Telescope (IMT) | VisionCare, Inc. | Age-related Macular Degeneration | 12/19 | 12/22 | | |
| Jayasundera, Thiran K |
| Recruiting | 1 | 20 | US | VP-001 | PYC Therapeutics | Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11 | 05/24 | 05/24 | | |
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene |
|
|
| Recruiting | N/A | 75 | Europe, US | | Splice Bio | Stargardt, Stargardt's Disease, Stargardt Disease, STGD1 | 12/26 | 02/27 | | |
NCT03349242: Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR) |
|
|
| Completed | N/A | 140 | Europe, Canada, US | | MeiraGTx UK II Ltd, Janssen, LP | Retinitis Pigmentosa | 04/24 | 04/24 | | |
NCT05573984: Natural History of PRPF31 Mutation-Associated Retinal Dystrophy |
|
|
| Recruiting | N/A | 50 | US, RoW | | PYC Therapeutics | Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive | 12/26 | 04/27 | | |
| Drada, Adriana |
| Recruiting | 3 | 150 | US | Sub-Retinal Administration of OCU400-301 | Ocugen | Retinitis Pigmentosa | 06/25 | 10/26 | | |
| Recruiting | 1/2 | 33 | Europe, US | SPVN06 | SparingVision | Retinitis Pigmentosa | 03/25 | 03/29 | | |
| Recruiting | 1 | 20 | US | VP-001 | PYC Therapeutics | Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11 | 05/24 | 05/24 | | |
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene |
|
|
| Recruiting | N/A | 75 | Europe, US | | Splice Bio | Stargardt, Stargardt's Disease, Stargardt Disease, STGD1 | 12/26 | 02/27 | | |
| Rao, Rajesh C |
NCT04627428: Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD) |
|
|
| Recruiting | 1/2 | 18 | US | RPESC-RPE-4W | Luxa Biotechnology, LLC, National Institutes of Health (NIH), National Eye Institute (NEI), Regenerative Research Foundation | Dry Age-related Macular Degeneration | 05/25 | 05/25 | | |
| Soto, Courtney |
| Recruiting | 1 | 20 | US | VP-001 | PYC Therapeutics | Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11 | 05/24 | 05/24 | | |
NCT05573984: Natural History of PRPF31 Mutation-Associated Retinal Dystrophy |
|
|
| Recruiting | N/A | 50 | US, RoW | | PYC Therapeutics | Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive | 12/26 | 04/27 | | |
| Bicket, Amanda |
| No trials found |
| Rudberg, Lindsay |
| No trials found |
